You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

387 Results
Blog post
The science of gathering and reporting on cancer burden data in Ontario began nearly a century ago, several years before the organization now known...
Oct 2018
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Inotuzumab Ozogamicin (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
inotuzumab ozogamicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
tamoxifen,
ribociclib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Document
Nov 2018
Document
Nov 2018
Guidelines and Advice
Status: Current
ID: GL 21-2v2
Version: 2
Nov 2018
Document
Jan 2019
Blog post
We spend an average of one-third of our waking hours at work, so it's important that our workplaces are safe and free from hazards. But for many...
Jan 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
triptorelin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Document
Mar 2019
Blog post
The first time Lauri P. met with her fellow patient and family advisors at Cancer Care Ontario, she was unprepared for the emotions stirred up by the...
Mar 2019

Pages